Argen X SE
Research Argen X SE (ARGX) on Bullrun: market cap USD 51.31B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARGX
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 51.31B
- Financial periodQ2 2026
- RevenueUSD 1.52B
- Net incomeUSD 472.00M
- Gross margin90.4%
Valuation Snapshot
latest market cap is USD 51.31B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.15B | USD 1.29B | USD 573.51M | 89.1% | 19.57 | USD 3.49B | USD 47.16M | USD 7.32B |
| FY2024 | USD 2.19B | USD 833.04M | -USD 151.05M | 89.6% | 12.78 | USD 1.50B | USD 39.05M | USD 5.50B |
| FY2023 | USD 1.23B | -USD 295.05M | -USD 464.14M | 90.4% | -5.16 | USD 2.05B | USD 20.00M | USD 4.10B |
| FY2022 | USD 410.75M | -USD 709.59M | -USD 966.63M | 92.8% | -13.05 | USD 800.74M | USD 12.43M | USD 2.81B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 51.31B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 52.04B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 37.37B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 22.48B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 20.96B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 18.09B | n/a | n/a | n/a |
About Argen X SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
ETFs that hold Argen X SE
Argen X SE is one of the ten largest holdings of 12 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 1.79% | 0.35% |
| iShares MSCI Europe Health Care Sector UCITS ETF | 3.44% | 0.18% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | 3.43% | 0.18% |
| Xtrackers MSCI Europe Health Care UCITS ETF 1C | 3.42% | 0.17% |
| BNP PARIBAS EASY EUR Overnight | 4.39% | 0.10% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | 3.30% | 0.46% |
| Harbor Health Care UCITS ETF - Accumulating | 2.92% | 0.89% |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc | 3.86% | 0.30% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Argen X SE's market cap?
Argen X SE's market capitalization is USD 51.31B.
What does Argen X SE do?
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).